Malignant hematologic cell

Malignant hematologic cells are the cancerous components of the hematopoietic system, encompassing a wide range of diseases such as leukemia, lymphoma, and multiple myeloma. These cells are defined by genetic alterations—including chromosomal translocations and point mutations—that drive uncontrolled expansion and survival within the bone marrow, blood, and lymphatic tissues [3, 10, 12]. While not a specific molecular target themselves, these cells express a variety of clinically relevant antigens and signaling proteins, such as CD20, CD38, and BCR-ABL1, which serve as the primary targets for precision therapies [8, 11]. Therapeutic strategies aimed at these cells include the use of monoclonal antibodies, small molecule inhibitors of oncogenic pathways, and cytotoxic chemotherapy [2, 6, 11]. The primary clinical objective is the selective elimination of these malignant clones to restore normal hematopoiesis, though this is often complicated by therapeutic resistance and significant side effects like myelosuppression and tumor lysis syndrome [3, 11].

Other names

Blood cancer cellHematopoietic malignant cellLeukemic cellLymphoma cellMyeloma cellNeoplastic hematologic cell

Drugs targeting malignant hematologic cells act by inducing apoptosis, inhibiting dysregulated intracellular signaling pathways (e.g., tyrosine kinase inhibition), or facilitating immune-mediated destruction through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 6, 12].